Separately, Piper Sandler assumed coverage on shares of Lexicon Pharmaceuticals in a report on Friday, August 12th. They issued an overweight rating and a $10.00 price objective for the company.
Lexicon Pharmaceuticals Stock Performance
LXRX stock opened at $2.19 on Monday. The company has a market capitalization of $413.31 million, a P/E ratio of -3.53 and a beta of 1.36. The company has a 50-day simple moving average of $2.27 and a 200 day simple moving average of $2.32. Lexicon Pharmaceuticals has a fifty-two week low of $1.31 and a fifty-two week high of $5.22. The company has a quick ratio of 7.54, a current ratio of 7.54 and a debt-to-equity ratio of 0.17.
Institutional Investors Weigh In On Lexicon Pharmaceuticals
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain.
- Get a free copy of the StockNews.com research report on Lexicon Pharmaceuticals (LXRX)
- Three Ways To Win The Online Gambling Industry
- Santa Claus Rally? Here’s What Needs to Happen
- Will the Return of Bob Iger Return the Magic to Disney Stock?
- Is Ardelyx is A Buy After Slip in Early 2022
- Is Tesla A Bargain Now As It Trades At Two-Year Lows?
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.